Clinical trials sponsored by Neurocrine Biosciences

Phase breakdown

Conditions studied

Recruiting trials led by Neurocrine Biosciences

• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT07196501 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 60 locations
• An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
  NCT07288320 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 9 locations
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
  NCT07227818 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 20 locations
• Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
  NCT07288333 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 6 locations
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
  NCT06963034 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 21 locations
• NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
  NCT07105098 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 15 locations
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
  NCT07114874 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 57 locations
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06786624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations

Common questions

How many trials is Neurocrine Biosciences recruiting for?

Neurocrine Biosciences is the lead sponsor of 11 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.